Home » Stocks » SVRA

Savara, Inc. (SVRA)

Stock Price: $1.75 USD 0.07 (4.17%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $1.80 +0.05 (2.86%) Apr 16, 7:59 PM
Market Cap 195.50M
Revenue (ttm) 257,000
Net Income (ttm) -49.62M
Shares Out 59.31M
EPS (ttm) -0.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $1.75
Previous Close $1.68
Change ($) 0.07
Change (%) 4.17%
Day's Open 1.68
Day's Range 1.60 - 1.79
Day's Volume 2,414,222
52-Week Range 1.00 - 3.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

Other stocks mentioned: ATNF, CTXR, JAGX, OCGN, TMBR, ZSAN
1 day ago - InvestorPlace

While penny stocks are always incredibly risky ventures, these publicly traded companies offer interesting catalysts to consider. The post 7 Penny Stocks with Interesting Catalysts appeared first on Inv...

Other stocks mentioned: BBKCF, ELYS, PTOTF, RFIL, VRME
1 week ago - InvestorPlace

Reddit stocks -- and in particular Reddit penny stocks -- are some of the riskiest shares out there. Yet, investors could make out big with some of the names on this list.

Other stocks mentioned: GME, LPCN, OGI, SNDL, YVR, ZOM
3 weeks ago - InvestorPlace

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: INFI, NBEV, FINV, SBBP
4 weeks ago - 24/7 Wall Street

Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today ...

Other stocks mentioned: ATNF, CTXR, MARA, SNDL, TXMD, ZOM
4 weeks ago - InvestorPlace

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

4 weeks ago - Zacks Investment Research

Savara Inc. (NASDAQ:SVRA) shares rallied Tuesday after Piper Sandler initiated coverage of the stock with an Overweight rating and $7 price target.

1 month ago - Benzinga

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of i...

1 month ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a p...

1 month ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in...

1 month ago - Business Wire

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company's pipeline, leadership, and business operations that are be...

4 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor he...

4 months ago - Business Wire

Savara is a rare lung disease company whose lead asset, Molgradex, failed to meet its primary endpoint in the Phase 3 IMPALA trial. Since that time, Savara has met with the FDA and has designed a new Ph...

4 months ago - Seeking Alpha

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual Lond...

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business updat...

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Boar...

7 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C.

7 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM.

7 months ago - Business Wire

Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.

7 months ago - Zacks Investment Research

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory...

7 months ago - Business Wire

Savara has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

7 months ago - Zacks Investment Research

Savara Inc (SVRA) CEO Robert Neville on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.

8 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord...

8 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business upda...

8 months ago - Business Wire

Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several Top Shorts...

Other stocks mentioned: BLNK, LQDA, NAVB
10 months ago - Forbes

Savara Inc. (SVRA) CEO Rob Neville on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Savara has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Savara Inc. (SVRA) CEO Rob Neville on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Savara (SVRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Savara Inc. (NASDAQ: SVRA) shares more than doubled on Monday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its autoimmune pu...

1 year ago - 24/7 Wall Street

These companies have a low financial burden.

Other stocks mentioned: I
1 year ago - GuruFocus

Shares of Savara Inc. SVRA, -6.42% tumbled 48% in premarket trade Wednesday, after the orphan lung disease company said the U.S.

1 year ago - Market Watch

Savara Inc. (SVRA) CEO Rob Neville on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Other stocks mentioned: ABEO, AGN, ALXN, AMGN, REGN
1 year ago - Zacks Investment Research

A host of factors pulled some stocks down.

Other stocks mentioned: CPS, HEXO
1 year ago - The Motley Fool

Investors just received some bad news about the company's lead drug candidate.

1 year ago - The Motley Fool

Shares of the thinly traded small-cap biotech Savara Inc (NASDAQ: SVRA) were plunging to a record low Thursday in the wake of a clinical trial readout from the company.

1 year ago - Benzinga

Savara Inc. (NASDAQ: SVRA) shares were absolutely crushed on Thursday after the company released its late-stage results for its treatment of autoimmune pulmonary alveolar proteinosis (aPAP).

1 year ago - 24/7 Wall Street

Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.

1 year ago - Zacks Investment Research

Shares in Savara Inc., which is seeking to address rare lung diseases, dropped 75% in after-hours trading Wednesday, when the drug company announced that a study failed to hit its target.

1 year ago - Market Watch

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Savara Inc (SVRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Savara Inc. (SVRA) CEO Rob Neville on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Savara Inc. (SVRA) CEO Rob Neville on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About SVRA

Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Industry
Biotechnology
CEO
Robert Neville
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
SVRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Savara stock is "Buy." The 12-month stock price forecast is 3.80, which is an increase of 117.14% from the latest price.

Price Target
$3.80
(117.14% upside)
Analyst Consensus: Buy